Recombinant antibodies are invented antibodies formed by using recombinant DNA technology. While traditional monoclonal ...

Collaboration to explore the immunoregulation of NK and T cells within the tumor microenvironment (TME) by CAPTN-3, with the goal of enhancing ...

Acquisition to strengthen key pillar of BioNTech’s oncology strategy aimed at establishing BNT327 as a pan-tumor technology platformfor the ...

Scientists have progressed from merely provoking an anti-cancer immune response to designing it ...

State Key Laboratory of Pharmaceutical Biotechnology, Medical School of Nanjing University, Nanjing 210093, China Department of Andrology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical ...

The colon cancer BRAFF mutation study is one of the first to be initiated under the FDA’s Project FrontRunner.

Global Gamma Delta T Cell Cancer Therapy Market Opportunity and Clinical Trials Insight 2030 Report Conclusions: Download ...

Acquisition to strengthen key pillar of BioNTech's oncology strategy aimed at establishing BNT327 as a pan-tumor technology platform for the treatment of advanced cancersWith the closing of the transa ...

MUNICH, Germany I January 30, 2025 I Tubulis announced today that its second drug candidate, TUB-030, has entered clinical evaluation with successful dosing ...

The European Medicines Agency has recommended three new medicines to treat breast and cervical cancer and ...

A phase 3 trial is evaluating ASP-1929 photoimmunotherapy plus Keytruda in first-line treatment for recurrent head and neck ...

Ypsilon Therapeutics, a portfolio company of 82VS, Alloy’s venture studio, has been awarded $2.7 million in seed funding from ...